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We have used a new ApoA-I transgenic mouse model to identify by global
gene expression profiling, candidate genes that affect lipid and lipoprotein
metabolism in response to fenofibrate treatment. Multilevel bioinformatical
analysis and stringent selection criteria (2-fold change, 0% false discovery
rate) identified 267 significantly changed genes involved in several molecular
pathways. The fenofibrate-treated group did not have significantly altered
levels of hepatic human APOA-I mRNA and plasma ApoA-I compared with
the control group. However, the treatment increased cholesterol levels
to 1.95-fold mainly due to the increase in high-density lipoprotein (HDL)
cholesterol. The observed changes in HDL are associated with the upregu-
lation of genes involved in phospholipid biosynthesis and lipid hydrolysis, as
well as phospholipid transfer protein. Significant upregulation was observed
in genes involved in fatty acid transport and b-oxidation, but not in those of
fatty acid and cholesterol biosynthesis, Krebs cycle and gluconeogenesis.
Fenofibrate changed significantly the expression of seven transcription
factors. The estrogen receptor-related gamma gene was upregulated
2.36-fold and had a significant positive correlation with genes of lipid and
lipoprotein metabolism and mitochondrial functions, indicating an impor-
tant role of this orphan receptor in mediating the fenofibrate-induced
activation of a specific subset of its target genes.
The Pharmacogenomics Journal (2010) 10, 165–179; doi:10.1038/tpj.2009.51;
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Introduction
Fibrates are important lipid-lowering drugs. They have been used in clinical
practice for more than three decades for the treatment of primary and secondary
dyslipidemias.1,2 In subjects with low high-density lipoprotein (HDL) levels,
fibrates have been shown to reduce triglycerides and increase HDL cholesterol,
without significantly affecting low-density lipoprotein (LDL) cholesterol, and to
decrease the mortality from coronary artery disease.3 Fibrates in the liver are
believed to act, at least in part, through the peroxisome proliferators-activated
receptor-alpha (Ppara). It is believed that ligands generated by fibrates bind and
activate moderately Ppara. Activated Ppara in turn heterodimerizes with retinoid
X receptor alpha (Rxra), binds to hormone response elements and activates the
target genes.4 Previous studies have suggested that fibrates promote lipolysis of
triglycerides by increasing the gene expression and the activity of lipoprotein
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lipase (Lpl),5,6 increasing the expression of Apoa57,8 and
decreasing the expression of Apoc3.9,10 Fibrates were shown
to promote b-oxidation of fatty acids (FA) by upregulating
various genes, including several genes of FA uptake and
b-oxidation.11–19 In rodents, fibrates downregulated the
expression of Apoa1,20 hepatic lipase13 and lecithin
cholesterol acyltransferase (Lcat)15 genes and upregulated
the expression of Apoa221 and phospholipid transfer protein
(Pltp).22 Previous studies of human ApoA-I transgenic Mice
and rabbits indicated that fenofibrate increase plasma ApoA-I
and HDL levels. The animal models used in these studies
carry the human transgene under the control of its proximal
promoter and also express their endogenous ApoA-I
gene.20,23,24
To obtain insights on the global molecular changes
(34000 genes) that contribute to lipid lowering and HDL
raising effects of fenofibrate, we used a new human ApoA-I
mouse model that expresses the human APOA-I gene under
the control of the proximal promoter and distal enhancer
sequences, in the background of Apoa1-deficient mice.
The fenofibrate treatment did not significantly alter the
expression of the human APOA-I gene and plasma ApoA-I
levels, but it increased HDL cholesterol to approximately
2-fold and shifted the HDL peak toward lower densities.
The expression of other genes involved in the biogenesis of
HDL was not affected. The increase in HDL cholesterol was
associated with the upregulation of genes involved in
phospholipid biosynthesis, phospholipid transfer in plasma
and in lipid hydrolysis.
Fenofibrate significantly upregulated genes that are
involved in fatty acid transport, b-oxidation and other
mitochondrial functions. These changes correlated posi-
tively with changes in the estrogen-related receptor gamma
(Esrrg) gene and negatively with changes in the T-rich
interactive domain 5b (Arid5b) gene, indicating involve-
ment of these transcription factors in the fenofibrate-
induced changes in gene expression.
Materials and methods
Animal models
The transgenic mice harboring the human APOA-I gene and
its regulatory sequences have been described previously.25
Briefly, the transgenic construct contains 2.1 kb of the 50
regulatory sequence along with 1.81 kb containing the
entire coding sequences of the APOA-I gene, a 1.6-kb
segment containing the intragenic sequence and the CAT
gene in front of the 890/þ24 regulatory sequence of the
APOCIII gene, that encompasses the common enhancer of
the APOA-I and APOCIII genes. In this construct, the
APOCIII gene was replaced by the CAT cDNA sequence.25
Treatment of ApoA-I transgenic mice with fenofibrate
Four-month old transgenic mice harboring the human
APOA-I gene and its regulatory sequence25 were separated
in four groups of five according to gender. Both the control
and the treatment groups were fed for 16 days with a diet
containing, as percent of calories, 18.2% proteins, 54.3%
carbohydrates, 27.5% fat along with vitamins and minerals
as described (Supplementary Table 1).26 The control group
continued on the same diet for 16 days, whereas the
treatment group received the same diet containing 31mg
fenofibrate/100 g diet. The daily dose of fenofibrate admi-
nistered in the diet was calculated to be equivalent of
160mg fenofibrate per 65 kg per day or 2.45mg per kg
body weight per day. This represents the pharmacological
dose administered to human subjects. Given that the
metabolic rate in mice is 12 higher than in humans, the
equivalent dose for a 25 g mouse was calculated to be
2.460.025 12¼0.74mgday1. This amount of feno-
fibrate corresponds to the consumption of B2.4 g diet per
day that contains B10kcal. Blood was collected from tail
vein on days 0 and 16 of the treatment period after 4h
fasting. At the end of the 16th day of the treatment, mice
were killed and the livers were collected, frozen in liquid
N2 and stored in 80 1C for further analyses. Microarray
analysis was carried out in the female mice group and the
corresponding controls.
RNA purification and analyses
Total RNA was purified from livers of human ApoA-I
transgenic mice that were frozen in liquid nitrogen and
stored in 80 1C, using the TRIzol Reagent (Invitrogen,
Carlsbad, CA, USA) according to the instructions of the
manufacturer.
The levels of Ppara and glyceraldehyde 3-phosphate
dehydrogenase (Gapdh) mRNAs were determined by north-
ern blotting and quantitated by phosphorimaging. The
Ppara probe was generated by PCR using as a template for
Ppara cDNA clone (cDNA clone MGC:18607 IMAGE:
4222384, Open Biosystems, Huntsville, AL, USA). The
primers used to generate the probes were as follows: Sense:
50-atgccagtactgccgttttc-30; antisense: 50-ggccttgaccttgttcatgt-
30. The mGapdh probe was 1.5 kb long and was generated by
PstI digestion of a rat Gapdh containing plasmid. The probes
were labeled with 32P using the random priming method.27
Real-time quantitative RT-PCR analysis
Hepatic gene expression levels of Esrrg and human APOA-I
were determined by reverse transcriptase-PCR (RT-PCR)
analysis and normalized against Gapdh expression levels.
For these analyses, 1 mg of RNA was initially treated with
DNase I (Ambion, Austin, TX, USA, DNA-free and Removal
Reagents) according to the manufacturer’s instructions. The
RNA samples were then reverse-transcribed using the
ThermoScript RT-PCR Kit (Invitrogen). Real-time quantita-
tive RT-PCR was carried out using an ABI PRISM 7700
Sequence detector (Applied Biosystems, Foster City, CA,
USA). Amplification was performed using SYBR Green PCR
Master Mix (Applied Biosystems). The primers used for PCR
amplification were as follows: 50-ggaagaattcgtcaccctca-30
(Esrrg-forward primer); 50-ttctgcacagcttccacatc-30 (Esrrg-re-
verse primer), 50-tccatgacaactttggcattg-30 (Gapdh-forward
primer) and 50-tcacgccacagctttcca-30 (Gapdh-reverse primer).
The primers used for amplification of human APOA-I were
purchased from TaqMan gene expression assays (ID
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HS00163641-mi) that amplify part of exon II and III. The
analysis was carried out using the Sequence Detection
Software 1.9.1 (Applied Biosystems). Duplicate reactions of
each sample were incubated for 2min at 50 1C, denatured
for 10min at 95 1C and subjected to 40 cycles of annealing at
55 1C for 20 s, with extension at 60 1C for 1min followed by
denaturation at 95 1C for 15 s.
Protein analysis
Hepatic homogenates from mice treated with control diet or
fenofibrate-containing diet were prepared by extensive
shaking of fresh or frozen livers in ice-cold lysis buffer
(10mM NaPO4, pH 7.2, 2mM EDTA, 10mM NaN3, 120mM
NaCl and 1% Nonidet P40) supplemented with a mixture
of protease inhibitors (Sigma-Aldrich, St Louis, MO, USA).
The samples were analyzed by sodium dodecyl sulfate-PAGE
and then transferred to polyvinylidene fluoride membranes.
The membranes were incubated with one of the following
primary antibodies: rabbit polyclonal anti-Ppara (1:250
dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
or goat polyclonal anti-Gapdh (1:1000 dilution). The
membranes were subsequently incubated with a peroxi-
dase-conjugated anti-rabbit or anti-goat (1:500 or 1:2000
dilution, respectively; Sigma-Aldrich) secondary antibody.
Protein signals were detected using enhanced chemilumi-
nescence reagents according to the manufacturer’s protocol
(Amersham Biosciences, Piscataway, NJ, USA).
Plasma lipids, ApoA-I and FPLC profiles
Total cholesterol and triglycerides of the plasma and the Fast
Protein Liquid Chromatography (FPLC) fractions were
determined as described28 using the WACO (WACO Chemi-
cal, Dalton, GA, USA) and INFINITY reagent thermo DNA
(Sigma-Aldrich) reagent kits, respectively, according to the
manufacturer’s instructions. Fractionation of plasma by
density gradient ultracentrifugation, electron microscopy
of the HDL fractions and non-denaturing two-dimensional
gel electrophoresis of plasma was performed as described.28
Plasma ApoA-I was determined by a turbidometric assay
using a commercially available kit (AutoKit apoA-I; WACO
Chemicals USA) as described.28
Target preparation, microarray hybridization and quality
assessment
Total RNA was extracted from the livers of 10 female human
ApoA-I transgenic mice. For RNA extraction, each liver
specimen was homogenized in Trizol (Life Technologies,
Rockville, MD, USA) and choloroform/isoamyl alcohol
(49:1). All RNA samples had a 28S/18S rRNA ratio close to 2
on 1.5% agarose gels, and absorbance ratios 260/280nm
between 1.9 and 2.1. A quantity of 6–8mg of each RNA sample
was used for target preparation. Targets were prepared as
previously described29 and hybridized to GeneChip Whole
Mouse Genome 430 2.0 Arrays (Affymetrix, Santa Clara, CA,
USA), which contain 45000 probe sets representative of over
39000 transcripts and variants from over 34000 well-
characterized mouse genes. The arrays were washed and
stained by the Affymetrix 450 Fluidics station, and scanned
using the GeneChip Scanner 3000, which was enabled for
high-resolution scanning. The GeneChip Operating Software
v1.4 (Affymetrix) was used to determine the expression level
and ‘present,’ ‘absent’ or ‘marginal’ call for each probe set.
Approximately 40–50% of the probe sets were called
‘present,’ indicating that these transcripts were present at
sufficient levels for accurate quantification. Target quality
was controlled for by ensuring that the expression of the
representative 30 and 50 sequences of the control genes
b-actin and Gapdh on the microarrays was o3-fold in all 10
data sets. The good hybridization quality was also estab-
lished through a concentration gradient of spike-in Bacillus
subtilis transcripts, which as desired, gave a ‘present’ call and
increasing expression levels in all data sets.
Analysis of microarray data
The first processing step was performed using the GeneChip
Operating Software v1.4. The resulting data were normalized
as previously described, to correct for uniform linear aberra-
tions of the reported signals between any two replicate
measurements, which may arise from idiosyncrasies during
the sample/array processing protocols.30 The data were then
filtered to keep only probe sets with more than three ‘present’
and one ‘marginal’ calls per probe set in the 10 data sets, and
therefore a reliable expression measurement. Approximately
22000 probe sets passed the filtering criteria.
Sample correlation coefficient (CC) analysis was carried
out on un-normalized, un-filtered data, to compare the
correlation of every pair of data sets/samples. In parallel,
hierarchical clustering was performed as described,31 using
the Cluster and TreeView Software (Berkeley, CA, USA)32
with centered linear correlation as a measure of similarity
using average linkage. For this analysis, only un-normalized
data were used, applying a range of standard deviation
thresholds.
Significant analysis of microarrays (SAM) was used to
identify significant gene expression changes between treated
and untreated mice.33 A two-class unpaired data analysis was
carried out on normalized and pre-filtered data (as described
above) using a D threshold of 2.265 and a fold threshold of 2.
The ‘D’ parameter enables the user to examine the effect of the
false-positive rate in determining significance, whereas fold is
calculated as the ratio of the average expression in treated
versus untreated mouse data sets. Only probe sets with 2-fold
change and a 0% median false discovery rate, the maximum
possible stringency, were selected. Functional annotation of
the significantly changed genes based on Gene Ontology
categories was performed using the GeneTools software (SCIE-
PLAS Ltd, Cambridge, UK).34
Transcription factors identified as significantly changed
by SAM in fenofibrate-treated mice were further analyzed by
the CC analysis to determine a potential association
between transcription factors and changed genes. In
particular, we calculated the CC between each of these
transcription factors and all other significantly changed
genes, taking into consideration the expression pattern of
each gene across all samples.
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Results
Effects of fenofibrate on hepatic APOA-I mRNA, plasma lipids and
ApoA-I and on lipoprotein profiles of the human ApoA-I transgenic
mice
The fenofibrate treatment, described in the Experimental
Procedures, decreased the levels of hepatic human APOA-I
mRNA and plasma ApoA-I of the treated group compared
with the control group, although the observed changes were
not statistically significant (Figure 1a). However, the plasma
cholesterol level was 1.95-fold higher in the treated group
than that in the control group (Figure 1b).
FPLC analysis results obtained from the control mice
showed that all the cholesterol was distributed in the HDL2
and HDL3 regions. In the fenofibrate-treated mice, the
increase in total cholesterol was accompanied by a shift of
HDL toward lower densities (HDL2/LDL/IDL) (Figure 1b),
which was also confirmed by density gradient ultracentri-
fugation of plasma. This analysis showed that in the
fenofibrate-treated group, the distribution of ApoA-I was
shifted toward HDL2/LDL/IDL and the ApoA-I levels
appeared reduced (Figures 1c and d). Electron microscopy
showed that HDL particles remained spherical (Figures 1e
and f). Two-dimensional gel electrophoresis showed that the
fenofibrate treatment did not alter the preb and aHDL
subpopulation of HDL (Figures 1g and h).
Fenofibrate induces distinct patterns of gene expression in the
human ApoA-I transgenic mice and affects multiple molecular
pathways
To determine the effect of fenofibrate treatment on gene
expression, we carried out sample CC analysis and hier-
archical clustering. Primary evidence confirming the fenofi-
brate effect on gene expression involved the reduced
intergroup (fenofibrate-treated vs untreated control mice)
CC values (92–97%) compared with intragroup (treated or
untreated mice) values (96–99%). Consistent with this
observation of reduced correlation between treated and
untreated mice, hierarchical clustering reproducibly distin-
guished treated from untreated mice based on their global
gene expression signatures for all standard deviation thresh-
olds applied and in all iterations (Figure 2a). Therefore,
fenofibrate appears to induce several changes in gene
expression in the liver.
SAM was applied on normalized and filtered data to
determine high fold and statistically significant gene
expression changes induced to the liver of human ApoA-I
transgenic mice by fenofibrate. After the application of
stringent thresholds (X2-fold and 0% false discovery rate),
313 probe sets, representative of 267 different genes and
expressed sequence tags (EST), were identified as highly and
significantly changed. As some significantly changed genes
were represented by multiple significantly changed probe
sets, the fold-change values presented for each gene are the
average of all its significantly changed probe sets. On the
basis of Gene Ontology categorization, the major functional
categories of differentially expressed genes were those
involved in transport, cell metabolism, including protein,
nucleic acid and organic acid, and cellular lipid metabolism
(Figures 2b and c). A large number of significantly
changed genes encoded for nuclear and mitochondrial
proteins, whereas other common categories included genes
that encode for endoplasmic reticulum, organelle, mem-
brane and cytoskeleton proteins (Figures 2b and c). The
list of the Gene Ontology classifications of all the signifi-
cantly changed probe sets is presented in the Supplementary
Table 2.
Effect of fenofibrate on genes involved in phospholipid biosynthesis
and the remodeling of HDL
In an attempt to explain the effects of fenofibrate on plasma
lipids and HDL levels, we have analyzed in detail the
changes in the expression of hepatic genes involved in lipid
and lipoprotein metabolism.
Fenofibrate downregulated 9.75-fold the expression of the
Apoa4 gene, and did not significantly alter the expression of
human APOA-I and several other genes that are involved in
the biogenesis and maturation of HDL such as Abca1, Lcat,
Abcg1, as well as the genes encoding proteins such as Apoa2,
Apoe and Apoc3, which are components of HDL.35,36
Fenofibrate upregulated 5.86-fold, the gene Pltp, and caused
a moderate 1.51-fold downregulation of Srb1, two genes that
are involved in the remodeling of HDL (Table 1).
The genes encoding the lipolytic enzymes Lpl and
pancreatic lipase-related protein 1 (Pnliprp1) were upregu-
lated 8.85- and 19.06-fold, respectively, whereas Apoa5 that
promotes lipolysis37 did not change (Figure 3, Table 1 and
Supplementary Table 2).
Fenofibrate also affected few genes that are involved in
phospholipid biosynthesis. Significant upregulation was
observed in monoacylglycerol acyl transferase 1 (Mogat1),
diacylglycerol kinase (Dgkh), phosphtidylinositol membrane
associated 1 (Pitpnm1), choline phosphotransferase (Chpt1)
and choline kinase a (Chka) genes, which were upregulated
19.78-, 2.24-, 2.74-, 2.33- and 2.09-fold, respectively
(Table 1). The corresponding proteins have an important
role in phospholipid biosynthesis.38 Some of these changes
are expected to have an effect on the synthesis of HDL.39
Effect of fenofibrate on genes affecting triglyceride hydrolysis, FA
transport, b-oxidation, other mitochondrial function, fatty acid
biosynthesis and carbohydrate metabolism
The monoglycerides generated by the actions of Lpl and
Pnliprp, which are upregulated, can be channeled toward
phospholipid biosynthesis. Significant upregulation was
also observed for the genes encoding the enzyme mono-
glyceride lipase (Mgll), which catalyzes the hydrolysis of
monoglycerides to FA and glycerol.40 Free FA generated by
the action of the lipolytic enzymes are channeled toward
b-oxidation (Figure 3).
Several genes encoding transporters of FA into the cells
including CD36 antigen (CD36), the FA transport protein 1
(Fatp1) or Slc27a1, and FA-binding proteins (Fabp3 and
Fabp2), as well as the gene encoding the VLDL receptor
(Vldlr) were upregulated 2.3- to 28.3-fold by fenofibrate
(Figure 3 and Table 1).
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A large number of genes encoding mitochondrial and
peroxisomal proteins were upregulated (Supplementary
Tables 2 and 3). The majority of these genes are involved
in b-oxidation of FA. This includes carnitine O-acetyl trans-
ferase (Crat) and carnityl-O-palmitoyl transferase 1b (Cpt1b),
which transport activated FA into the mitochondria, as well
0
0.2
0.4
0.6
0.8
1
1.2
Control 
re
la
tiv
e 
hu
m
an
 A
po
A-
I 
m
-R
N
A
 le
ve
ls
NS
0
50
100
150
200
250
300
350
400
Control
hu
m
an
 A
po
A-
I c
on
ce
nt
ra
tio
n
 
(m
g/d
l)
NS
0
5
10
15
20
25
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Fraction number
 
Ch
ol
es
te
ro
l (m
g/d
l) Control Untreated
TC 300 ± 34.17mg/dl
TG 34.39 ± 5.76 mg/dl
FF Treated
TC 585 ± 57mg/dl
TG 58 ± 19 mg/dl
Fenofibrate Fenofibrate
IDL/LDL
pre β α HDL pre β α HDL
Control untreated mice
Control untreated mice
Fenofibrate treated mice
Fenofibrate treated mice
Lipid free
ApoA-l
ApoA-l
3 μg
Lipid free
ApoA-l
ApoA-l
3 μgHDL2 HDL3 IDL/LDL HDL2 HDL3
M M
1.
02
68
1.
03
11
1.
04
41
1.
06
84
1.
07
92
1.
10
3
1.
12
46
1.
16
04
1.
16
98
1.
20
93
1.
02
64
1.
03
33
1.
04
33
1.
06
99
1.
07
67
1.
10
01
1.
12
46
1.
14
61
1.
16
89
1.
20
93
Figure 1 (a) Hepatic human APOA-I mRNA and plasma ApoA-I levels of individual ApoA-I transgenic mice treated with either a control or a
fenofibrate-containing diet. (b) FPLC profiles of total cholesterol of ApoA-I transgenic mice fed a diet containing fenofibrate (FF) or without
fenofibrate (control). (c and d) Fractionation of the plasma of ApoA-I transgenic mice fed the control (c) or fenofibrate-containing diet (d) by density
gradient ultracentrifugation and analysis of the fractions by sodium dodecyl sulfate (SDS)-PAGE. The densities of the fractions are indicated at the
top of the figures. (e and f) Electron microscopy pictures of the HDL fractions of ApoA-I transgenic mice fed the control (e) or fenofibrate-containing
diets (f). The photomicrographs were taken at 750000 magnification and enlarged thrice. (g and h) Two-dimensional gel electrophoresis of
plasma of the control (g) or the fenofibrate (h)-containing diets.
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as several genes involved in the b-oxidation pathway.
Among those are genes encoding the mitochondrial en-
zymes acyl CoA thiol esterases 2 and 9 (Acot2 and Acot9)
and the peroxisomal enzymes acyl CoA thiol esterases 4, 6
and 8 (Acot4, Acot6 and Acot8), dodecenoyl CoA delta iso-
merase (Dci), and enoyl CoA hydratase (Ehhadh). Signifi-
cant upregulation was also observed for the genes encoding
the mitochondrial uncoupling proteins 2 and 3 (Ucp2 and
Ucp3) and the cytosolic Acot1 gene. All these genes were
upregulated 2.06- to 6.13-fold (Figure 3 and Table 1).
Fenofibrate upregulated the expression of the genes
encoding malic enzyme (Mod1), stearoyl CoA desaturase
(Scd1) and elongation of very long-chain FAs (Elovl3)
2.67- to 3.32-fold, which may have a role in the biosynthesis
of unsaturated FA and long-chain FA (Figure 3 and Table 1).
The expression of genes encoding enzymes of lipogenesis,
glycolysis, gluconeogenesis and the Krebs cycle did not
change significantly. Few changes pertinent to these pathways
include 2.49- to 8.87-fold upregulation of pyruvate dehydro-
genase kinase 4 (Pdk4), phosphomannomutase 1 (Pmm1) and
galactose kinase-1 (Galk1) genes and a 2.08-fold downregula-
tion of the fructose biphosphatase (Fbp1) gene (Table 1).
Figure 3 depicts the significantly changed genes in res-
ponse to fenofibrate and their potential contribution in
phospholipid biosynthesis, and the remodeling of HDL, as
well as in triglyceride hydrolysis, FA transport and lipid
catabolism.
Associations between transcription factors and lipid-related
genes in response to fenofibrate treatment
Our analysis showed that the transcription factor coding
genes Esrrg, Jun oncogene (Jun), Lim homeobox protein 6
(Lhx6) and E2F transcription factor 8 (E2f8) were upregu-
lated 2.36-, 3.22-, 2.93- and 2.06-fold, respectively, whereas
the transcription factor coding genes Arid5b, Nigfi A binding
protein 2 (Nab2) and Kruppel-like factor 13 (Klf13) were
downregulated 2.08-, 2.22- and 2.04-fold, respectively, in
response to fenofibrate treatment. To explore the potential
transcriptional mechanisms involving these factors, we
performed a CC analysis for each of the seven significantly
changed transcription factors against the remaining 312
significantly changed probe sets, as identified by SAM.
These 2184 (3127) CC values obtained from this
analysis ranged between 0.4189 and 0.9899. The CC value
between the multiple probe sets of each significantly
changed gene ranged from 0.7561 to 0.9985 and the average
CC was 0.9466. Probe sets representing different genes of the
same family had significantly lower CC than 0.9400 (for
example, Pla2g6 and Pla2g7 had CC¼0.6400–0.7500).
Therefore, genes with CC X0.9400 are considered to have
highly similar expression patterns and could be potentially
functionally related. The number of genes that had CC
40.9400 for each of the transcription factors is shown in
Figure 4a.
The Esrrg transcription factor gene had the highest CC to
the largest number of probe sets (89 probe sets CC
40.9400), and particularly to lipid-related genes (20 probe
sets), including lipid metabolism (for example, Mod1,
Mogat1, Acot2, Acot8, Pltp, ApoA4, Dci and Cte1) and lipid
transport (for example, Slc27a1, Cd36, Vldlr and Atp9a)
(Figure 4b and Supplementary Tables 3 and 4). To test the
putative role of Esrrg in our data, we analyzed the CC of
Esrrg to all 45 000 probe sets on the arrays, and filtered for
CC X0.9400. Esrrg correlated strongly with 268 probe sets.
Of the 268 probe sets, 71 were related to metabolism, 50 of
the genes encode mitochondrial proteins, 34 were lipid
related and 21 were specifically involved in electron
transport (data not shown). Esrrg may therefore represent a
mediator of the fenofibrate effect on lipid metabolism and
mitochondrial function.
The gene encoding a Arid5b had a CC 40.9400 with 79
probe sets and showed a highly similar but inverse
correlation pattern to that observed for Esrrg (CC¼0.966).
Figure 2 (a) Hierarchical clustering of the global gene expression
profiles in the liver of control (Ctr) and fenofibrate-treated (Fen). Two
distinct branches are evident in the dendrogram, representative of the
different patterns of gene expression in Ctr and fenofibrate-treated
animals when un-normalized filtered data were used. (b) Major Gene
Ontology level-5 categories corresponding to the 244 significantly
overexpressed probe sets. An asterisk (*) marks all lipid metabolism-
related categories. (c) Major Gene Ontology level-5 categories
corresponding to the 69 significantly underexpressed probe sets.
An asterisk (*) marks all lipid metabolism-related categories.
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Table 1 Fold change of genes implicated in lipid and HDL metabolism in the fenofibrate-treated human apoA-I transgenic mice
Gene name Symbol Fold
Fatty acid binding protein 3, muscle and heart Fabp3 28.28
Monoacylglycerol-O-acyltransferase 1 Mogat1 19.78
Pancreatic lipase related protein 1 Pnliprp1 19.06
Pyruvate dehydrogenase kinase, isoenzyme 4 Pdk4 8.87
Lipoprotein lipase Lpl 8.85
Acyl-CoA thioesterase 1 /// acyl-CoA thioesterase 2 Acot1 /// Acot2 6.59
Solute carrier family 27 (fatty acid transporter), member 1 Slc27a1 6.23
Acyl-CoA thioesterase 2 Acot2 6.13
Phospholipid transfer protein Pltp 5.86
Acyl-CoA thioesterase 1 Acot1 5.69
Carnitine palmitoyltransferase 1b, muscle Cpt1b 5.67
CD36 antigen Cd36 4.68
Very low density lipoprotein receptor Vldlr 4.26
Hydroxysteroid (17-beta) dehydrogenase 11 Hsd17b11 3.96
Phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) Pla2g7 3.91
Malic enzyme, supernatant /// similar to NADP-dependent malic enzyme (NADP-ME) (Malic
enzyme 1)
LOC624892 /// LOC677317 ///
Mod1
3.32
Jun oncogene Jun 3.22
Phospholipase A2, group VI Pla2g6 3.20
Enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase Ehhadh 3.14
Uncoupling protein 2 (mitochondrial, proton carrier) Ucp2 3.09
Carnitine acetyltransferase Crat 3.01
LIM homeobox protein 6 Lhx6 2.93
Acyl-CoA thioesterase 6 Acot6 2.83
Peroxisomal biogenesis factor 11a Pex11a 2.76
Phosphatidylinositol membrane-associated 1 Pitpnm1 2.74
Stearoyl-Coenzyme A desaturase 1 Scd1 2.67
ATPase, class II, type 9A Atp9a 2.52
Elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 Elovl3 2.53
Dodecenoyl-Coenzyme A delta isomerase (3,2 trans-enoyl-Coenzyme A isomerase) Dci 2.38
Estrogen-related receptor gamma Esrrg 2.36
Uncoupling protein 3 (mitochondrial, proton carrier) Ucp3 2.35
Monoglyceride lipase Mgll 2.34
Choline phosphotransferase 1 Chpt1 2.33
Fatty acid binding protein 2, intestinal Fabp2 2.32
Acyl-CoA thioesterase 9 Acot9 2.31
Diacylglycerol kinase, eta Dgkh 2.24
Choline kinase alpha Chka 2.09
Acyl-CoA thioesterase 4 Acot4 2.08
Acyl-CoA thioesterase 8 Acot8 2.06
E2F transcription factor 8 E2f8 2.06
CD14 antigen Cd14 2.04
3-hydroxy-3-methylglutaryl-Coenzyme A lyase Hmgcl 1.71
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 Hmgcs1 1.63
Peroxisome proliferator activated receptor gamma Pparg 1.59
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 Hmgcs2 1.30
ATP-binding cassette, sub-family G, member 1 Abcg1 1.29
Catalase Cat 1.15
Diacylglycerol O-acyltransferase 1 Dgat1 1.14
Fatty acid synthase Fasn 1.13
ATP-binding cassette, subfamily A, member 1 Abca1 1.10
Apolipoprotein A-V Apoa5 1.07
Apolipoprotein A-I-binding protein Apoa1bp 1.08
Apolipoprotein A-II Apoa2 1.17
Diacylglycerol O-acyltransferase 2 Dgat2 1.17
Apolipoprotein E ApoE 1.19
Acetyl-Coenzyme A carboxylase Acaca 1.21
Sterol regulatory element binding transcription factor 1 Srebf1 1.21
Sterol regulatory element binding transcription factor 2 Srebf2 1.22
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For every high positive CC of a probe set to Esrrg, Arid5b
showed a high negative CC, and vice versa. Of the 79 probe
sets, 16 were lipid-related, 7 were involved in lipid transport,
6 were mitochondrial and 3 were peroxisomal genes (Figure
4c and Supplementary Tables 4 and 5).
Klf13 had negative CC to multiple significantly changed
probe sets, several of which were related to lipid metabolism
and lipid transport (for example, Vldlr, Acot9, Mogat1 and
Slc27a1), cytochrome-related (for example, Cyp4f14 and
cytochrome c oxidase subunit Vlb polypeptide 2 (Cox6b2)) and
proteolysis-related (for example, Ctse) genes (Supplementary
Table 3). Lhx6 correlated positively with six probe sets
including Pdk4, whereas Jun, Erf8 and Nab2 correlated
positively with four, two and one probe sets, respectively
(Supplementary Table 3).
Fenofibrate does not alter hepatic Ppara gene expression, but
increase cellular Ppara levels and hepatic Esrrg mRNA levels
The microarray analysis did not detect significant changes
in the hepatic expression of the Ppara gene and showed a
1.5- and 2.03-fold reduction in the expression of Ppara
coactivators 1a and 1b (Pgc1a and Pgc1b), respectively
(Table 1). The lack of increase in PPARa mRNA level was
confirmed by northern blot analysis (Figures 5a and c).
However, the protein levels of Ppara were increased in the
liver of the fenofibrate-treated mice (Figure 5b). In agree-
ment with our microarray results, RT-PCR analysis of hepatic
RNA showed that the Esrrg gene was significantly upregu-
lated in fenofibrate-treated ApoA-I transgenic mice (Figure
5d). The combined effect of fenofibrate on the transcription
factors Ppara, Esrrg and Arid5b in mitochondrial and
cytosolic genes affecting lipid metabolism and HDL synth-
esis and remodeling is shown in Figure 6 and explained
further in the Discussion section.
Discussion
This study used a new ApoA-I transgenic mouse model in
order to decipher by global gene expression profiling the
mechanism through which fenofibrate affect genes of lipid
and lipoprotein metabolism.
The multilevel bioinformatical analysis of the microarray
data identified significant changes in numerous genes
involved in relatively few, yet central biological processes.
Although all the observed changes may have important
implications, our analysis has focused on the effect of
fenofibrate on genes that affect HDL biogenesis and
remodeling, as well as lipid metabolism and transcription
factors related to the observed changes.
Table 1 Continued
Gene name Symbol Fold
Lecithin:cholesterol acyltransferase Lcat 1.26
Apolipoprotein C-III Apoc3 1.34
3-hydroxy-3-methylglutaryl-Coenzyme A reductase Hmgcr 1.38
Peroxisome proliferator activated receptor alpha Ppara 1.39
Scavenger receptor, class B, type I Srb1 1.51
Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha Ppargc1a (Pgc1a) 1.54
Peroxisome proliferative activated receptor, gamma, coactivator 1 beta Ppargc1b (Pgc1b) 2.03
Kruppel-like factor 13 Klf13 2.04
AT rich interactive domain 5B (Mrf1 like) Arid5b 2.08
Hydroxysteroid 11-beta dehydrogenase 1 Hsd11b1 2.20
Ngfi-A binding protein 2 Nab2 2.22
Phospholipase A1 member A Pla1a 2.33
Apolipoprotein A-IV Apoa4 9.75
Abbreviation: HDL, high-density lipoprotein.
Fold changes reaching statistical significance are marked in bold. Changes in important genes of lipid and HDL metabolism that did not reach statistical significance are
also included. For genes represented by more than one probe sets on the 430 2.0 Affymetrix arrays, the average of all the probe sets is presented.
Triglycerides Monoacylglycerol
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Free F.A.
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Figure 3 Pathways of lipid and lipoprotein metabolism affected by
fenofibrate. Upregulation of genes involved in phospholipid biosynth-
esis, HDL synthesis and remodeling. Upregulation of genes involved in
lipolysis, FA transport, b-oxidation, synthesis of unsaturated fatty acids
and long-chain fatty acids.
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Effect of fenofibrate on the expression of the human ApoA-I gene
and on plasma HDL levels
The mouse model used in this study expresses the human
APOA-I gene under the control of its regulatory sequences
that include the proximal promoter and the APOCIII
enhancer in ApoA-I-deficient background. This mouse
model has two advantages. It can record reliably the changes
in human APOA-I gene transcription in vivo. In addition, due
to the inactivation of the endogenous mouse Apoa1 gene,
the mouse synthesizes HDL that contains human APOA-I as
its major protein.25 The lipid analysis of plasma showed that
there was a 1.95-fold increase in the total cholesterol in the
fenofibrate-treated mice and a shift of HDL toward lower
densities, compared with the control group. The increase in
total plasma cholesterol was the result of the increase in
HDL cholesterol. The treatment did not change the profile
of the HDL subpopulations as determined by two-dimen-
sional gel electrophoresis.
Real-time PCR analysis showed that in the fenofibrate-
treated group, there was a small decrease in the expression
of the human APOA-I gene that was not statistically
significant. A similar small non-statistically significant
decrease was also detected in plasma ApoA-I levels of the
fenofibrate-treated mice. Two previous studies suggested
that fenofibrate caused 2- to 2.6-fold increase in human
APOA-I gene expression in ApoA-I transgenic mice, as well as
a 3.5- to 7.5-fold increase in plasma ApoA-I levels.20,23 These
increases did not occur in ApoA-I transgenic mice in the
PPARa-deficient background.23 In ApoA-I transgenic rabbits,
the higher doses of fenofibrate used increased hepatic
human ApoA-I mRNA levels and plasma ApoA-I levels
approximately 1.6- and 2-fold, respectively.24
It has been reported that fenofibrate downregulates the
expression of Apoa1 gene in mice, whereas they upregulate
the expression of the human ApoA-I.20 The different
responses of the human and mouse Apoa1 genes to the
fenofibrate treatment was attributed to differences between
the human and rodent Apoa1 promoter.41 This study shows
that the in vivo regulation of the human apoA-I gene in mice
when it contains its proximal and distal regulatory
sequences resembles the regulation of the mouse Apoa1
gene described previously.20
The observed differences between the present and the
previous studies,20,23,24 can be explained based on the
mechanism of transcriptional regulation of the human
APOA-I gene that emerged from in vitro and in vivo studies.25
In the transgenic mice used here, the expression of the
human APOA-I gene was controlled by the proximal
promoter and the distal APOCIII enhancer. In the transgenic
mice and rabbits used in previous studies,20,23,24 the
transgene lacked the APOCIII enhancer and the transcrip-
tion of the APOA-I gene was driven by the proximal APOA-I
promoter alone.42,43 We have shown previously that in the
transgenic mice where the APOCIII enhancer is inactivated,
the intestinal transcription of the APOA-I gene is abolished
and the hepatic transcription is reduced to 20% compared
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with mice that carry both the proximal promoter and the
APOCIII enhancer.25,44
The proximal human APOA-I promoter contains two
hormone response elements between nucleotides 210 to
197 and 132 to 119, which can bind Rxra/Ppara
heterodimers. In addition, the human APOCIII enhancer
contains an hormone response element between nucleo-
tides 736 to 721, which can bind Rxra/Ppara hetero-
dimers.44 On the basis of our knowledge on how the human
APOA-I transgene is regulated in vivo, it is expected that in
the fenofibrate-treated mice, the expression of the human
APOA-I gene will be controlled by interactions between
Rxra/Ppara heterodimers bound to the proximal promoter
and the distal enhancer, as well as the interactions of the
distantly bound Rxra/Ppara heterodimers with SP1.25,44
These interactions, that may affect positively or negatively
gene expression, are not possible in the transgenic mice
that lack the APOCIII enhancer used in the previous
studies.20,23,24
Effect of fenofibrate on the expression of genes that may affect
the synthesis of HDL
Current advances in HDL research indicate that the initial
step in the biogenesis of HDL is the extracellular lipidation
of lipid-poor ApoA-I by the action of ABCA1 lipid transpor-
ter.45 Important steps for the maturation of HDL are the
esterification of HDL of the nascent particles by Lcat, the
transfer of lipids by Pltp, the cholesteryl ester transfer
protein and the interaction of the HDL with the HDL
receptor (SR-BI) and the ABCG1 lipid transporter.28,35,45
The fenofibrate treatment significantly downregulated
(9.75-fold) the expression of Apoa4 gene. A 10-fold decrease
in the Apoa4 gene expression was previously observed in the
rat liver by clofibrate treatment.18 In addition, the feno-
fibrate treatment caused small but not statistically signifi-
cant changes in the expression of mouse Apoc3, Apoa2,
Apoa5 and Apoe genes, as well as in other genes that are
involved in the biogenesis and maturation of HDL such as
Abca1, Lcat and Abcg1 (Table 1). Overall, the increase in HDL
could not be accounted for by the upregulation of Apoa1
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Figure 6 Schematic representation of the effect of fenofibrate on
genes affecting lipid and lipoprotein metabolism and mitochondrial
functions, as well as the role of the transcription factors Esrrg, Ppara, the
coactivators Pgc1a and Pgc1b and Arid5b in this process. Direct effects
may involve transcriptional activation of the Ppara gene by Esrrg,
stabilization of Ppara by ligands, activation by coactivators and
synergistic interactions between Esrrg and Ppara on the promoters of
fenofibrate-inducible genes. Indirect effects may involve the Esrrg-
mediated negative regulation of Arid5b expression, which may
influence Ppara gene expression.
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and Apoa2 as suggested previously20,21 or attributed to the
changes in several other genes implicated in the biogenesis
of HDL.
Consistent with the previous reports, the fenofibrate
treatment upregulated 5.85- and 8.85-fold the expression
of the Pltp and Lpl genes, respectively.6,22 The function of
the Pltp protein is to transfer phospholipids from VLDL, IDL
and LDL to HDL. It has been shown recently that a 3-fold
increase in the Pltp activity in transgenic mice reduces the
plasma HDL levels and promotes atherogenesis.46 Thus, the
Pltp-mediated phospholipid transfer cannot explain the
observed increase and the shift of the HDL peak to the
lower density region in response to fenofibrate treatment.
On the other hand, increase in Lpl is associated with increa-
sed plasma HDL levels.47 Previous studies indicated that
fenofibrate promotes the degradation of Srb1.48 Thus,
increased degradation of Srb1 combined with the observed
1.51-fold reduction in Srb1 gene expression may have
contributed to some extent to the increase in the size of
HDL.49
The increase in the HDL levels could be also affected by
the increased expression of genes involved in phospholipid
biosynthesis. This study showed that the fenofibrate treat-
ment caused significant changes in the genes involved
in phospholipid biosynthesis, including Mogat1, Dgkh,
Pitpnm1, Chpt1 and Chka (Table 1). Furthermore, the over-
expression of the Mogat1 gene (19.8-fold increase) is
expected to promote the generation of diacylglycerol from
monoacylglycerol, and the overexpression of Dgkh is
expected to further promote the generation of diacylglycerol
phosphate, which is used in phospholipid biosynthesis.
Finally, the overexpression of Chka will promote phospho-
choline biosynthesis and the overexpression of Pitpnm1,
which regulates DAG consumption via the CDP–choline
pathway, may promote phosphatidylcholine biosynthesis.38
A previous study showed that the biosynthesis of phospha-
tidylcholine in the liver is important for HDL formation.39
Overall, the upregulation of the genes involved in phos-
pholipid biosynthesis as well as that of Lpl may account for
the observed increase in HDL levels, and the modest
downregulation of the Srb1 gene may account for the
increase in the size of HDL in response to fenofibrate
treatment.
The lipid lowering and other actions of fenofibrate
As depicted in Figure 3, fenofibrate significantly upregulated
the genes involved in lipolysis of Lpl, Pnliprp1 and Mgll, as
well as several genes involved in FA transport and
b-oxidation. The combined action of Lpl and Pnliprp1
enzymes converts triglycerides to monoglycerides, which
can be converted to free FAs and glycerol by the action of
Mgl1.40 The hydrolysis of triglycerides of chylomicrons and
VLDL by the Lpl reduces plasma triglyceride levels and
promotes the clearance of the resulting lipoprotein rem-
nants by the LDL receptor, which recognizes and endo-
cytoses ApoB- and ApoE-containing lipoproteins.50,51 The
monoglycerides that are produced by the action of Lpl and
Pnliprp1 can be used for the synthesis of phospholipids that
are incorporated into the HDL and other lipoproteins. The
free FA produced by the action of the lipolytic enzymes are
transferred by the lipid transporters into the mitochondria
and undergo b-oxidation.
Acetyl CoA generated by the b-oxidation enters the Krebs
cycle for energy production. We observe significant upregu-
lation of the gene encoding Pdk4, which inactivates the
pyruvate dehydrogenase complex, by phosphorylating the
pyruvate decarboxylase activity of the complex. This ensures
the use of fat rather than carbohydrate as a source of energy
production for the cell.52 Thee genes related to glycolysis,
gluconeogenesis and the Krebs cycle did not show signifi-
cant changes in expression (Table 1). The observed down-
regulation of Fbp1 in response to fenofibrate treatment is
also consistent with inhibition of gluconeogenesis. Finally,
the upregulation of Galk1 will favor the entry of galactose
into the glycolytic pathway.
In this study, we did not observe changes in the expres-
sion of other genes such as Apoc3 and Apoa5 that have been
implicated in plasma triglyceride clearance.7–9 Thus, it
appears that the increased expression of Lpl and Pnliprp1
genes that facilitates lipolysis and lipoprotein remnant
clearance, combined with increased uptake and b-oxidation
of FA, may account for the lowering of plasma triglycerides
in response to fenofibrate treatment. The upregulation of
Up2 and Up3 by fenofibrate may represent a complemen-
tary mechanism to reduce the concentration of the reactive
oxygen species.53 Previous studies have also described upre-
gulation of some but not all of the genes of lipid metabolism
shown in Table 1 and Figure 3, including triglyceride
lipolysis,5,6 FA transport54,55 and b-oxidation.11,12,56-58
In agreement with previous studies,58 we did not find
significant changes in the lipogenic genes in response to
fenofibrate treatment. The upregulation of both Scd-1,
which has been observed previously,59 and Elovl3 suggest
that fibrates may promote synthesis of unsaturated FA and
long-chain FA. Free FA, that are the substrates of Scd1 and
Elovl3, may be produced from the hydrolysis of VLDL by the
action of Lpl, by de novo synthesis of FA in the cytoplasm, or
by both processes. Acetyl CoA required for FA synthesis can
be generated in the cytosol from citrate by the action of
citrate lyase. Mitochondrial citrate is exchanged for the
cytosolic malate, which can be produced by Mod1. The
upregulation of the gene encoding Mod1 by fenofibrate is
consistent with previous findings60 and will favor increased
production of acetyl CoA in the cytoplasm.
The role of transcription factors in the fenofibrate-induced
activation of the target genes
Genes with high CC to each other are likely to participate in
common molecular pathways and/or to be co-regulated at
the gene transcriptional level. The microarray analysis
showed that the transcription factors Esrrg, Lhx6 and Jun
and E2f8 were upregulated approximately 2- to 4-fold,
whereas the transcription factors Arid56, Nab2 and Klf3
were downregulated approximately 2-fold in response to
fenofibrate treatment (Table 1). The 2.36-fold upregulation
of Essrg was confirmed by RT-PCR analysis.
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The Esrrg gene had the highest CC to the other
significantly changed genes, particularly those involved in
lipid metabolism and transport (Supplementary Table 3).
Esrrg, together with Esrra and Esrrb, belong to the family
of orphan nuclear hormone receptors identified initially
based on their homology to the estrogen receptor ERa.61
The estrogen receptor-related proteins encoded by the
corresponding Esrra, b and g genes, have been implicated in
the regulation of genes involved in energy production,
cellular FA uptake, FA oxidation, mitochondrial electron
transport and oxidative phosphorylation.62,63 Esrra-
and Esrrg-mediated regulation of target gene occurs
in part through the direct activation of Ppara gene
transcription, using Ppargc 1a or 1b (Pgc1a and Pgc1b) as
coactivators.64–67
In this study, fenofibrate did not cause significant changes
in the hepatic expression of the Ppara gene (1.39-fold
reduction) as assessed by the microarray analysis and
confirmed by northern blotting. However, the protein levels
of Ppara were increased in the liver of the fenofibrate-treated
mice. This observation is consistent with previous findings
showing that fibrates decrease Ppara mRNA levels68,69 but
increased protein levels.68 This effect may be due to the
binding of fenofibrate to Ppara that may also increase its
stability in addition to increasing its transcriptional activity.
Small upregulation (1.59-fold) was observed in the Pparg
gene (Table 1). In addition, the fenofibrate treatment caused
1.5- and 2.03-fold reduction in the expression of Pgc1a and
Pgc1b genes, respectively, which are key coactivators of
genes involved in mitochondrial oxidative metabolism as
well as other cellular energy metabolic pathways.67,70–74 It is
possible that Esrrg may bind to the promoters of fenofibrate-
inducible genes and in synergy with Ppara may activate
their transcription. It has been reported that in mouse
fibroblast double-deficient for Ppara and Esrra, the addition
of Esrra or Ppara alone fails to activate several Ppara target
genes, and supports the concept of synergy between these
two transcription factors in the activation of Ppara-inducible
genes.75 It is interesting that the increase in Esrrg gene
expression is sufficient to activate Ppara and its target genes
despite the decrease in expression of the coactivators Pgc1a
and Pgc1b genes.
The Arid5b gene expression showed a strong negative
correlation to Esrrg, and to most of the lipid metabolism
genes for which Esrrg had a positive correlation. Arid5b is
considered as a negative regulator of transcription, although
its precise functions have not been clearly established.76
In our case, it is possible that the reduced expression of
Arid5bmay contribute to the increased expression of Esrrg or
it may enhance its transcriptional activation functions. It is
also possible that Arid5b acts as a repressor of the Ppara
promoter activity, and when it is downregulated, either
directly by fenofibrate or indirectly by Esrrg, it may promote
activation of the Ppara gene and the fenofibrate-inducible
genes, even when the Pgc1 levels are reduced.
On the basis of the CC analysis, it appears that down-
regulation of Klf13 may favor the transcriptional activation
of other genes involved in lipid metabolism.
The combined effect of fenofibrate on the transcription
factors Ppara, Esrrg, Arid5b and other transcription factors
affecting lipid and lipoprotein metabolism is shown in
Figure 6. In this scheme Ppara, in synergy with Esrrg,
controls directly the expression of specific genes of lipid and
lipoprotein metabolism and mitochondrial functions. It is
also possible that Esrrg may contribute by inhibiting Arid5b
gene expression, thus preventing further downregulation of
Ppara gene expression.
Currently, there is an intense interest to increase HDL
levels in humans by affecting either ApoA-I synthesis
or any other protein involved directly or indirectly in the
biogenesis of HDL. This study, in addition to its contribu-
tion to the molecular mechanism underlying the pharma-
cological action of the fibrates, establishes that the new
human ApoA-I transgenic mouse model described here is an
optimal model to study molecules that affect the synthesis
of HDL.
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